Related Experiment Video
Updated: Mar 5, 2026

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
The epigenetic landscape of clear-cell renal cell carcinoma
Katarzyna Kluzek1, Hans A Bluyssen1, Joanna Wesoly1
1Department of Human Molecular Genetics, Laboratory of High Throughput Technologies, Institute of Molecular Biology and Biotechnology, Faculty of Biology, Adam Mickiewicz University in Poznan, Umultowska 89, 61-614 Poznan, Poland.
Abstract:
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of all kidney tumors. During the last few years, epigenetics has emerged as an important mechanism in ccRCC pathogenesis. Recent reports, involving large-scale methylation and sequencing analyses, have identified genes frequently inactivated by promoter methylation and recurrent mutations in genes encoding chromatin regulatory proteins. Interestingly, three of detected genes (PBRM1, SETD2 and BAP1) are located on chromosome 3p, near the VHL gene, inactivated in over 80% ccRCC cases. This suggests that 3p alterations are an essential part of ccRCC pathogenesis. Moreover, most of the proteins encoded by these genes cooperate in histone H3 modifications. The aim of this review is to summarize the latest discoveries shedding light on deregulation of chromatin machinery in ccRCC. Newly described ccRCC-specific epigenetic alterations could potentially serve as novel diagnostic and prognostic biomarkers and become an object of novel therapeutic strategies.
Insights
Epigenetic alterations, particularly in chromosome 3p genes like PBRM1, SETD2, and BAP1, are crucial in clear cell renal cell carcinoma (ccRCC) development. These changes in chromatin regulation offer potential for new diagnostic and therapeutic approaches in ccRCC.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Clear cell renal cell carcinoma (ccRCC) is the predominant kidney tumor subtype.
- Epigenetics, especially DNA methylation and gene mutations, plays a significant role in ccRCC pathogenesis.
- Alterations in chromatin regulatory proteins are frequently observed in ccRCC.
Purpose of the Study:
- To review recent advancements in understanding the deregulation of chromatin machinery in ccRCC.
- To highlight the significance of epigenetic modifications in ccRCC.
- To explore the potential of ccRCC-specific epigenetic alterations as biomarkers and therapeutic targets.
Main Methods:
- Large-scale methylation and sequencing analyses were employed.
- Identification of frequently inactivated genes via promoter methylation.
- Recurrent mutation analysis in chromatin regulatory genes.
Main Results:
- Genes such as PBRM1, SETD2, and BAP1 on chromosome 3p, near the VHL gene, are frequently altered.
- Inactivation of these 3p genes occurs in over 80% of ccRCC cases.
- The proteins encoded by these genes are involved in cooperative histone H3 modifications.
Conclusions:
- Alterations in chromosome 3p are fundamental to ccRCC pathogenesis.
- Epigenetic modifications in ccRCC present opportunities for novel diagnostic and prognostic biomarkers.
- These findings may pave the way for new therapeutic strategies targeting ccRCC.
More Related Videos
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Tumor Microenvironment
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

